<div class="headers"><div>Supplementary Table 1. Subgroup analyses of change in HbA1c by baseline HbA1c </div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; text-align: left;'></td>
<td style='border-top: 2px solid grey; text-align: left;'></td>
<td style='border-top: 2px solid grey; text-align: left;'></td>
</tr>
<tr>
<td style='text-align: left;'></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Placebo (N = 108)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Dapagliflozin 10 mg (N = 108)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">HbA1c in patients with baseline HbA1c <8% (<64 mmol/L), % [mmol/mol], LA, n Baseline (SD) Adjusted mean change (95% CI) Placebo-subtracted change (SE)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">42 7.44 (0.34) [58 (3.7)] -0.42 (-0.63 to -0.21) [-4.6 (-6.9 to -2.3)]</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">49 7.32 (0.54) [56 (5.9)] -0.79 (-1.00 to -0.57) [-8.6 (-10.9 to -6.2)] -0.36 (0.11) [-3.9 (1.2)]</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">HbA1c in patients with baseline HbA1c >8% to <9% (>64 to <75 mmol/mol), % [mmol/mol], LA, n Baseline (SD) Adjusted mean change (95% CI) Placebo subtracted change (SE)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">46 8.37 (0.27) [68 (3.0)] -0.04 (-0.20 to 0.13) [-0.4 (-2.2 to 1.4)]</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">41 8.35 (0.30) [68 (3.3)] -0.68 (-0.85 to -0.51) [-7.4 (-9.3 to -5.6)] -0.64 (0.12) [-7.0 (1.3)]</p></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="padding-left:20px; " class="indent1 ">HbA1c in patients with baseline HbA1c >9% (>75 mmol/mol), % [mmol/mol], LA, n Baseline (SD) Adjusted mean change (95% CI) Placebo-subtracted change (SE)</p></td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="padding-left:20px; " class="indent1 ">20 9.64 (0.52) [82 (5.7)] 0.18 (-0.19 to 0.54) [2.0 (-2.1 to 5.9)]</p></td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="padding-left:20px; " class="indent1 ">18 9.51 (0.43) [80 (4.7)] -0.64 (-0.99 to -0.29) [-7.0 (-10.8 to -3.2)] -0.82 (0.18) [-9.0 (2.0)]</p></td>
</tr>
</tbody>
</table>
